Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand

다국어 초록 (Multilingual Abstract)

Background: In 2013, the Thai Pediatric Oncology Group (ThaiPOG) introduced a national protocol in which high-dose chemotherapy plus stem cell rescue is performed without immunotherapy.Methods: This study aimed to elucidate the outcomes of high-risk neuroblastoma (HR-NB) patients treated with the ThaiPOG protocol. This retrospective cohort review included 48 patients (30 males, 18 females) with a median age of 3 years (range, 8 months to 18 years) who were treated at 5 ThaiPOG treatment centers in Thailand in 2000–2018.Results: Eight of the 48 patients showed MYCN amplification. Twenty-three patients (48%) received 131I-meta-iodobenzylguanidine prior to high-dose chemotherapy and stem cell rescue. The majority of patients achieved a complete or very good response prior to consolidation treatment. The 5-year overall survival (OS) and event-free survival (EFS) rates were 45.1% and 40.4%, respectively. Patients aged >2 years had a nonsignificantly higher mortality risk (hazard ratio [HR], 2.66; 95% confidence interval [CI], 0.92–7.68; P=0.07). The MYCN amplification group had lower OS and EFS rates than the MYCN nonamplification group, but the difference was not statistically significant (45% OS and 37.5% EFS vs. 33.3% OS and 16.6% EFS; P=0.67 and P=0.67, respectively). Cis-retinoic acid treatment for 12 months was a strong prognostic factor that could reduce mortality rates among HR-NB patients (HR, 0.27; 95% CI, 0.09–0.785; P=0.01).Conclusion: High-dose chemotherapy plus stem cell rescue followed by cis-retinoic acid for 12 months was well tolerated and could improve the survival rates of patients with HR-NB.

참고문헌 (Reference)

1 Matthay KK, "Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group" 341 : 1165-1173, 1999

2 Pannelli F, "Survival trends of childhood cancer during the period 1978-1994 in Italy : a first report from the Italian cancer registries" 25 : 354-375, 2001

3 Wiangnon S, "Survival rate of children with neuroblastoma in Srinagarind hospital" 18 : 154-159, 2003

4 Jain R, "Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta" 38 : 291-304, 2021

5 Lau L, "Neuroblastoma : a single institution’s experience with 128 children and an evaluation of clinical and biological prognostic factors" 19 : 79-89, 2002

6 Group TTPO, "National protocol for the treatment of childhood cancer 2018" Sahamitr Printing and Publishing 237-247, 2018

7 Berthold F, "Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma : a randomised controlled trial" 6 : 649-658, 2005

8 Matthay KK, "Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid : a Children’s Oncology Group study" 27 : 1007-1013, 2009

9 Trahair TN, "Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation" 40 : 741-746, 2007

10 Haghiri S, "Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue" 56 : 1984-1997, 2021

11 Pritchard J, "High dose melphalan in the treatment of advanced neuroblastoma : results of a randomised trial(ENSG-1)by the European Neuroblastoma Study Group" 44 : 348-357, 2005

12 Rujkijyanont P, "Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen : a prospective multicenter study" 19 : 961-, 2019

13 Jain R, "Autologous stem cell transplant for high-risk neuroblastoma : achieving cure with low-cost adaptations" 67 : e28273-, 2020

14 Yu AL, "Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma" 363 : 1324-1334, 2010

15 Lasorsa VA, "19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis" 5 : 18-, 2020